PP
VNDA icon

Paloma Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Paloma Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-14,021
Closed -$135K – 2265
2020
Q3 		$135K Buy
+14,021
New +$150K ﹤0.01% 1862
2017
Q1 		– Sell
-52,823
Closed -$843K – 2260
2016
Q4 		$843K Buy
52,823
+10,190
+24% +$164K 0.01% 1259
2016
Q3 		$710K Buy
42,633
+25,483
+149% +$343K 0.01% 1240
2016
Q2 		$192K Buy
+17,150
New +$166K ﹤0.01% 1981
2015
Q2 		– Sell
-21,525
Closed -$200K – 1953
2015
Q1 		$200K Buy
+21,525
New +$243K 0.01% 1086
2014
Q4 		– Sell
-24,961
Closed -$259K – 1388
2014
Q3 		$259K Buy
+24,961
New +$327K 0.01% 766

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Paloma Partners's VNDA Position: Q4 2020 in Review

Paloma Partners sold out of Vanda Pharmaceuticals (VNDA) in Q4 2020, closing a stake of 14,021 shares — an estimated $135K sold.

Paloma Partners first reported a position in VNDA in Q3 2014 and held it in 6 quarters. The position peaked at $843K in Q4 2016. 178 funds tracked by Wall St. Rank hold VNDA as of Q4 2020.

  • Paloma Partners reported no remaining Vanda Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Paloma Partners sold 14,021 Vanda Pharmaceuticals shares in Q4 2020, an estimated $135K.
  • Paloma Partners first reported a position in Vanda Pharmaceuticals in Q3 2014 and held it in 6 quarters.
  • Paloma Partners's Vanda Pharmaceuticals position peaked at $843K in Q4 2016.
  • 178 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.